Brief Communication: Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university
Abstract Background We assessed the willingness of female students at a Ugandan public university to use long-acting Cabotegravir (CAB-LA) for HIV prevention, given their high prevalence of HIV risk behaviours. Methods Using an online questionnaire, this cross-sectional study surveyed 346 female und...
Saved in:
Main Authors: | Bridget Atuhaire, Laban Muteebwa, Racheal Nabunya, Richard Muhindo, Tom Denis Ngabirano, Charles Peter Osingada, Patience A. Muwanguzi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-12-01
|
Series: | AIDS Research and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12981-024-00686-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV
by: Maria Mazzitelli, et al.
Published: (2024-12-01) -
HIV Replication Under High-Level Cabotegravir Is Associated with the Appearance of 3′-PPT Mutations, Circular DNA Transcription and Recombination
by: Xierong Wei, et al.
Published: (2024-11-01) -
Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084
by: Sinead Delany‐Moretlwe, et al.
Published: (2025-01-01) -
PrEP15-19 Choices: an implementation study protocol of HIV prevention with oral and long-acting injectable cabotegravir PrEP in real-world settings among sexual and gender minority adolescents in Brazil
by: Inês Dourado, et al.
Published: (2025-01-01) -
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics
by: Katerina A. Christopoulos, et al.
Published: (2024-11-01)